Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2,...

Full description

Bibliographic Details
Main Authors: Iuliia G. Samoilova, Olga E. Vaizova, Anastasia E. Stankova, Mariia V. Matveeva, Daria V. Podchinenova, Dmitry A. Kudlay, Anastasiia A. Borozinets, Tatyana A. Filippova, Ivan R. Grishkevich, Anastasia V. Partala, Diana A. Gerasimova
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2024-01-01
Series:Терапевтический архив
Subjects:
polymorphism
dipeptidyl peptidase-4 inhibitors
type 2 diabetes mellitus
glp1r
tcf7l2
dpp-4
kcnq1
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/628985/144486

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/628985/144486

Similar Items